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Abstract: Positron emitting radionuclides are used to label different compounds, allowing the study
of the major biological systems using PET (positron emission tomography) imaging. Although there
are several radionuclides suited for PET imaging, routine clinical applications are still based on
a restrict group constituted by 18F, 11C, and, more recently, 68Ga. However, with the enlarged
availability of low-energy cyclotrons and technical improvements in radionuclide production,
the use of unconventional radionuclides is progressively more common. Several examples of
unconventional radionuclides for PET imaging are being suggested, and 45Ti could be suggested
as a model, due to its interesting properties such as its abundant positron emission (85%), reduced
positron energy (β+ endpoint energy = 1040 keV), physical half-life of 3.09 h, and interesting chemical
properties. This review aims to introduce the role of cyclotrons in the production of unconventional
radionuclides for PET imaging while using 45Ti as an example to explore the potential biomedical
applications of those radionuclides in PET imaging.
Keywords: cyclotron; PET; titanium-45; unconventional radionuclides
1. Introduction: Unconventional Radionuclides for PET Imaging
The incorporation and utilization of technological developments in clinical routine is becoming
normal in modern practice of medicine. The application of imaging modalities is improving the quality
of medical care and procedures that are available in medicine, which is an attitude that enhances
the rapid implementation of modern paradigms of evidence-based medicine and science-based
medicine. In fact, medical imaging occupies a primary position in clinical decision algorithms. In such
context, non-invasive imaging modalities could allow for accurate diagnoses, increase precision in
treatment choice/planning, and provide opportunities to follow the evolution of the clinical status
of patients [1]. These modalities could also act over wide ranges of time and size scales involved in
biological and pathological processes. Multiple imaging techniques are available, including X-ray
imaging, computerized tomography (CT), magnetic resonance (MR) imaging, ultrasonography (US),
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optical imaging using fluorescent molecules (OF), and nuclear medicine (NM) using radioisotopes for
different procedures such as planar imaging, single photon emission computed tomography (SPECT)
and positron emission tomography (PET) [2].
Nuclear medicine has been an independent medical specialty since 1972, and is defined by
the World Health Organization (WHO) as one that “encompasses applications of radioactive materials
in diagnosis, treatment, or in medical research, with the exception of the use of sealed radiation sources in
radiotherapy” [3]. In practice, nuclear medicine procedures are methods and techniques based in
radionuclides. For diagnostic purposes, nuclear medicine uses primarily two types of radionuclides:
(i) gamma-photon emitting nuclides (the ones that decay by isomeric transition or electron capture) for
planar imaging and SPECT; and (ii) positron emitting nuclides for PET, which will be deeply discussed
along this paper.
Radionuclides are used to label very small amounts of a pharmaceutical compound of
interest, creating radiopharmaceuticals. According to the decay type of the nuclide component,
the radiopharmaceutical can be optimized for a given procedure (SPECT versus PET). This industry of
radiopharmaceuticals in general present a significant impact at the economical level. According to
recent reports, the global radiopharmaceuticals market in 2017 was evaluated in $5.5 billion USD [4].
There are several factors that enhance the success of the application of a certain radionuclide.
Considerations such as the physicochemical properties, availability, cost, and ease of use are some of
the most relevant. For instance, according the literature, the usual clinical practice of PET imaging relies
just on four radionuclides, namely: carbon-11 (11C), nitrogen-13 (13N), oxygen-15 (15O), and fluorine-18
(18F). All of them are characterized by relatively short physical half-lives [5]. The commercially available
radiopharmaceuticals are almost invariably associated with 18F, due to the technical constraints in the
production and distribution processes of the other short-lived nuclides. In fact, radiopharmaceuticals
labeled with 18F are very interesting and commonly used mainly because of physical properties,
such as a period of half-life that allows local (in situ) production and short-medium scale distribution,
and the low β+ energy endpoint, which guarantees a good image quality [6].
Recently, a global trend was observed of exploring several new radionuclides for PET imaging
that were different than the most classical ones, in order to increase the range of applications of
the technology, as well as diversify the radiolabeled compounds. This become possible due to
new insights into the production processes, radiolabeling methodologies, and interest in clinical
applications of different radionuclides [7]. Examples of these unconventional radionuclides for PET
imaging are: Scandium-44 (44Sc), Titanium-45 (45Ti), Cobalt-55 (55Co), Copper-60/61/64 (60/61/64Cu),
Bromium-76 (76Br), Rubidium-82 (82Rb), Yttrium-86 (86Y), Technetium-94m (94mTc), Zirconium-89
(89Zr), and Iodine-124 (124I) [8,9]. Recently published papers confirm the investigational trend
underlined in this paper [10–12]. The correspondent physical properties are presented in Table 1.
Table 1. Some unconventional positron emission tomography (PET) radionuclides and corresponding
physical properties [13].
Radionuclide Half-Life β+ Endpoint Energy (MeV)
44Sc 3.927 h 1.47
45Ti 3.1 h 1.04
55Co 17.53 h 1.50
60Cu 23.7 min 3.77
61Cu 3.333 h 1.21
64Cu 12.700 h 0.653
76Br 16.2 h 3.94
82Rb 1.273 min 3.15
86Y 14.7 h 3.14
89Zr 3.3 day 0.902
94mTc 52.0 min 2.44
124I 4.176 day 2.14
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As already cited, conventional applications of PET imaging are based on organic elements with
short half-lives (minutes to hours). A careful analysis of the radionuclides listed in Table 1 shows
a tendency to explore radionuclides with higher physical half-lives and chemical characteristics
associated with metallic elements (inorganic elements). In fact, the use of nuclides of inorganic
elements has been studied since the discovery of radioactivity, but nuclear properties are principal
factors that justify the development of the new compounds, while the availability of radionuclides in
high specific activities and inorganic chemistry issues at the radiotracer level are the most frequent
challenges [14]. Even so, unconventional radiometals are gradually being introduced, diversifying the
available tools and procedures in nuclear medicine, particularly in PET imaging.
2. Cyclotrons and the Production of Unconventional Radionuclides
Today, more than 2700 radionuclides have been produced artificially with particle accelerators [15].
In addition, a few examples are also being obtained in loco using radionuclide generators through
radioactive decay.
PET radionuclides, in particular, can be produced in cyclotrons, especially using inducing (p,n)
nuclear reactions in the targets of stable isotopes.
Routine cyclotron production processes are made possible by the actual dissemination of
these devices. As a matter of fact, by the end of 2005, there were 262 cyclotrons operating in the
39 member states of International Atomic Energy Agency (IAEA); however, it was believed that
around 350 cyclotrons were operating in the whole world, according to a database of the agency [16].
Unfortunately, there is no official update of this report, because it is not easy to correctly estimate the
number of cyclotrons operating nowadays all over the world.
The commercially available cyclotrons can be classified with respect to the particle type and
maximum energy reached, the method of ion production, the technique of beam extraction from the
cyclotron (or absence of extraction), the intensity of the accelerated ion beams, and other specific
properties or features [17,18]. There are different classifications based on the type and energy of
the accelerated particles [17,19]. Independently from the classification used, an important aspect to
mention is that near 70% of the cyclotrons disseminated over the world are low-energy cyclotrons
(≤20 MeV) [16].
According to empirical and practical evidence, the cyclotrons that typically have been applied
worldwide in radionuclide production comprise properties such as: (i) the capability of accelerating
negative ions (H−); (ii) beam extraction using stripper foils; (iii) fixed beam energy between 10–18 MeV,
or 10–24 MeV mainly if the installation is intended for the production of many radionuclides, large-scale
production and/or research purposes; (iv) fixed frequency of the RF generator; (v) two or four dees
placed in valleys; (vi) internal ion source(s); (vii) the possibility of adjusting the beam position on the
target; (viii) possibility of multi-target irradiations; (ix) compact radiation shielding around the device
(“self-shielded” cyclotron); and (x) a high level of automation and simplicity in maintenance.
Despite the existence of the formal classifications, cyclotrons that respect the criteria stated in the
last paragraph are normally classified by professionals of the field as “small cyclotrons”, “low-energy
cyclotrons” or even as “medical cyclotrons”, and are applied to induce (p,n) reactions, which are
typically low-energy processes with a constant onset below 9 MeV [20].
After the careful optimization of technical details such as targetry and irradiation parameters,
high production yields of some of the unconventional radionuclides covered in this paper have been
obtained in cyclotrons [21–26]. Examples of such radionuclides and recommended nuclear reactions
are given in Table 2.
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Table 2. Examples of cyclotron-produced unconventional PET radionuclides.












As more research studies in radionuclide production are delivered with successful results,
which are conjugated with promising results in the preclinical and clinical trials that are currently
being developed, these “unconventional” radionuclides are set to play an increasingly important role
in nuclear medicine. These considerations highlight the pivotal role that cyclotrons have in solving the
availability issues of interesting radionuclides for PET imaging [21].
3. Titanium-45 and Its Applications
Among the different examples that could be used to explore the paradigm of unconventional
radionuclides for PET imaging in analysis, 45Ti is an interesting case study.
The nuclide 45Ti has a half-life of 3.09 h, which allows for distribution within a broader region
than radiopharmaceuticals based on 18F or other shorter half-life radionuclides. On the other hand,
its decay is predominantly based on positron emission (85%), with a maximum positron energy of
1040 keV and an average energy of 439 keV, which assures good image quality in PET images.
Preliminary results that were obtained in the experimental program of our group revealed the
production feasibility of 45Ti in low-energy cyclotrons through the use of a 45Sc(p,n)45Ti nuclear
reaction, with proton beams higher than 3 MeV. The maximum cross-section values were determined
for proton beams with energy in the range between 10–14 MeV, while significant impurities production
was found for energies higher than 17 MeV (see Table 3). These results mean that the development of
a routine production process is possible, and research on the subject is ongoing [27].
Table 3. Preliminary results of experimental cross-section values for 45Sc(p,n)45Ti nuclear reaction.
Mean Beam Energy (MeV) Cross-Section (mbarn) Uncertainty (mbarn)
16.1 ± 1.0 1.2 × 102 ±0.4 × 102
15.3 ± 1.0 2.1 × 102 ±0.7 × 102
12.4 ± 0.9 4.4 × 102 ±1.4 × 102
8.9 ± 0.8 3.4 × 102 ±1.0 × 102
4.9 ± 0.7 1.2 × 102 ±0.4 × 102
3.4 ± 0.7 0.8 × 101 ±0.3 × 101
In addition, the chemical properties of Ti allow two different scenarios for developing
radiopharmaceuticals: (i) the “direct” labeling of ligands using chelation chemistry and/or simple
covalent bounds with ligands of interest; or (ii) radiolabeled nanoparticles (either to label nanoparticles
that are already explored in the field of nuclear medicine, or to label titanium oxide nanoparticles that
could be relevant for clinical purposes).
The first reference to a potential application of 45Ti belongs to a Japanese research team, and was
published in 1981 by the Cyclotron and Radionuclide Center (CYRIC) of Tokohu University [28].
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This group simultaneously evaluated the production, target chemistry (extraction and purification of
45Ti), and radiochemistry (labeling), and conducted some animal experiments. The main conclusion
was centered on the potential of 45Ti-compounds to become “a new series of the positron-emitting
radiopharmaceutical”, even considering some problems related to the stability of 45TiCl4 [28]. Examples
of 45Ti-phytate and 45Ti-DTPA images are shown in Figure 1.
Some years later, the same group reported the use of other 45Ti-labeled compounds, namely
45TiOCl2 and 45TiO-phytate, as potential colloid agents for imaging the reticuloendothelial system.
They also indicated 45Ti-DTPA (diethylenetriaminepentaacetic), 45Ti-citrate, and 45Ti-HSA (human
serum albumin) as possible agents for estimating blood volume and indicators of the breakdown of
the blood–brain barrier [29].
Considering the beginning of the study on the pathway of incorporation of titanium-based
anticancer drugs such as budotitane(C24H28O6Ti), 45Ti-budotitane was prepared and incorporated
into liposomes to provide optimal tumor targeting [30]. Apart from this work, no further experimental
studies were found on biodistribution or imaging using this compound.
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Figure 1. Whole body images of 45Ti-phytate (A) and 45Ti-DTPA (diethylenetriaminepentaacetic)
(B) acquired 10 minutes (A1 and B1) and 60 minutes (A2 and B2) after injection in rats. Images
published by Ishiwata et al. in 1981 [28].
After a gap of some years, Vavere et al. [31] reported an evaluation study of 45Ti as a radionuclide
for PET imaging. Despite other considerations, it was reported that the cyclotron production and
purification of 45Ti is feasible. The work also demonstrated a clear spatial resolution observed down to
a rod diameter of 1.25 mm using a Derenzo phantom, i.e., a resolution comparable with 18F, only with
a slight degradation due to the higher energy endpoint and consequent range widening of positrons
emitted by 45Ti (see Figure 2) [31].
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Another study of Vavere and Welch [32] produced 45Ti and used small animal imaging with
45Ti-transferrin, which provided new insights about the mechanism of action of a new class of cytostatic
agents based on titanium complexes. This research performed a direct labeling of apotransferrin with
45Ti and studied the resultant biodistribution. The microPET images provided indications on the
increased uptake of 45Ti-transferrin in tumors, with retention up to 24 h, demonstrating that titanium
radiopharmaceuticals could be explored as new tools for the in vivo imaging of tumors [31]. This data
also supports the use of 45Ti-labeled compounds in theranostics and personalized medicine, taking the
ability to select patients for a specific type of treatment into account.
However, Price et al. [33] published a work reporting some problems regarding the purification
of 45Ti to be used in the radiolabeling process of transferrin. They reported losses of up to 53% of the
45Ti activity in the waste fractions during the separation process. However, it seems to be a problem
with this particular experiment, because other authors have achieved good radiochemical yields in the
labeling of proteins such as transferrin or Df-antibody [34].
In general, the reappearance of titanium-based drugs to treat cancer has been met with
some success. The several chemical steps that are needed to stabilize these new titanium-based
antineoplastics are being developed. In this research, the ligand salan seems to play a special role and
lead to a significant investment in the development of these titanium-based drugs [35,36]. However,
it is also known that the phase of drug development represents a highly complex, inefficient and costly
process that usually takes huge amounts of time and money. Again, nuclear medicine imaging can
be decisive, enhancing the efficiency of selecting the candidate drugs that should move forward into
clinical trials or be abandoned [37]. The conjugation of the need for more information about drug
pharmacokinetics, and the added value of nuclear medicine in the drug development process, can be
used strategically; 45Ti labeling of compounds of interest could boost the research on titanium-based
drugs. In fact, this conceptual idea is not totally original, because already published data shows the
use of 45Ti-salan compounds as translational tools to help these drugs in the passage from fundamental
research to clinical applications (example in Figure 3) [38].
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However, the concept can be even taken further, if one hypothesizes that 45Ti compounds could act
as diagnostic imaging agents of the same cancers that could be hereafter treated with titanium-based
drugs. This once again suggests a role for 45Ti in theranostics and personalized medicine.
In the paradigm of personalized medicine, nanoparticles are being studied as drug delivery
systems, and their application as vectors for radionuclide-based molecular imaging is a powerful
tool of growing interest [39]. Indeed, in another context, recent data suggests that functionalized
titanium dioxide nanoparticles (TiO2) can be surface-engineered to target cancer cells [40–44].
Thus, the radiolabeling of TiO2 nanoparticles with 45Ti could constitute a tool to provide in vitro
biodistribution studies, which can also allow the in vivo monitoring of its biological distribution
and the pharmacokinetics of such drug delivery systems. The nanoparticle radiolabeling could be
achieved by different methodologies, including activation methods and synthesis based on radioactive
precursors [45]. However, apart from other advantages related to the specific activity obtained,
synthesis based on radioactive precursors appears to be the simplest and most favorable option, mainly
due to the coincidence between the nanoparticle chemical nature (titanium) and the radionuclide that
is aimed to be used for radiolabeling (45Ti). Figure 4 presents an overview of the processing steps to
radiolabel TiO2 nanoparticles by the method suggested above.
To implement the process presented in Figure 4, once the cyclotron production of 45Ti seems to be
feasible, our group looks for optimizing all of the technical aspects. Then, the extraction of 45Ti from
the solid target constitutes a formidable challenge due to pharmaceutical requirements and technical
issues, such as the specific activity needed. The task will require, for sure, wet chemistry techniques to
fulfill the predefined requisites. The use of radioactive precursors for the labeling of TiO2 nanoparticles
was already mentioned and briefly justified, but special attention should be given to the reduction of
preparation time, because the operation is actually very time-consuming. Finally, 45TiO2 nanoparticles
should be purified, filtered by size, and controlled regarding the surface properties for the appropriate
targeting of biological processes.
As a final note, our literature review made on 45Ti found only one non-oncological application
where labeled cations were used for the investigation of cerebral neurodegeneration [46].
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Figure 4. Possible approach to obtain 45TiO2 nanoparticles using the cyclotron irradiation of a solid
target of 45Sc.
4. Conclusion and Future Perspectives
Over the last decades, significant efforts have been made in the fundamental study, testing,
development, and optimization of radionuclide production processes. The achievements have
benefited the field of medical imaging and, particularly, radionuclide imaging using nuclear medicine
methods and techniques. PET presents some advantages that could be used in accordance with the
actual paradigms of medicine, in such a way that truthfully modern and personalized medical care
could be conducted on patients. The wider use of low-energy cyclotrons is playing a crucial role
in increasing the availability of radionuclides for preclinical or clinical trials, diversifying the set of
radionuclides available for biomedical applications.
Several unconventional radionuclides for PET are being suggested to be introduced in
clinical practice, because of the diversity of pathophysiological processes that could be studied.
55Co, 60/61/64Cu, 76Br, 82Rb, 86Y, 89Zr or 124I represent examples of this trend. This review focused on
the exploration of 45Ti as a reliable candidate for PET imaging, emphasizing again the importance of
cyclotrons to provide the production of the radionuclide. The titanium-45 half-life of 3.09 h, together
with low energy positrons, were key factors for its selection as an interesting candidate. Potential
Instruments 2018, 2, 8 8 of 10
applications of 45Ti include some possibilities that have been proposed and briefly studied by other
groups, such as imaging with 45Ti-transferrin to study titanium-based chemotherapy agents or with
45Ti-salan compounds to be applied in theranostics of cancer. The use of 45TiO2 nanoparticles here
suggested is an innovative proposal that should be developed in the near future.
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